🔴 Upstream Bio, Inc. is trading 9.9% down today on volatility tied to clinical trial data and gene-therapy sentiment

Upstream Bio, Inc. is trading 9.9% down at $7.28 following a sharp intraday selloff despite a lack of new company-specific news or SEC filings.

• The decline extends recent volatility linked to previous coverage of clinical trial data and shifting sentiment within the broader gene-therapy sector.
• Major U.S. indices remain relatively flat, indicating the move is likely stock-specific and driven by investor sentiment rather than broader market trends.